Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Shionogi & Co. Ltd. (OTC: SGIOY).

Full DD Report for SGIOY

You must become a subscriber to view this report.


Recent News from (OTC: SGIOY)

FDA OKs revised labeling for ViiV Healthcare HIV meds to include risk of birth defects
The FDA has signed off on new labeling for ViiV Healthcare's HIV meds TIVICAY (dolutegravir), TRIUMEQ (abacavir, dolutegravir and lamivudine) and JULUCA (dolutegravir, rilpivirine) to include information on the risk of neural tube defects (birth defects of the brain, spine or spinal cord). P...
Source: SeekingAlpha
Date: September, 06 2018 16:48
Entasis Therapeutics files for $86.25M initial public offering
Clinical-stage biopharmaceutical firm Entasis Therapeutics has filed for an initial public offering for up to $86.25M. More news on: Tetraphase Pharmaceuticals, Shionogi & Co. Ltd. ADR, GlaxoSmithKline, Healthcare stocks news, IPOs, Read more ...
Source: SeekingAlpha
Date: August, 17 2018 18:15
Shionogi & Co. Ltd. ADR 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by Shionogi & Co. Ltd. ADR in conjunction with their 2018 Q1 earnings Read more ...
Source: SeekingAlpha
Date: July, 31 2018 14:58
FDA OKs Shionogi's lusutrombopag for low blood platelets in certain patients; ADRs up 7%
The FDA approves Shionogi's ( OTCPK:SGIOF +2.9% )( OTCPK:SGIOY +7.1% ) Mulpleta (lusutrombopag) for the treatment of thrombocytopenia (low blood platelets) in chronic liver disease patients at increased risk of bleeding when undergoing invasive procedures. More news on: Shionogi &...
Source: SeekingAlpha
Date: July, 31 2018 13:52
ViiV Healthcare's two-drug HIV regimen successful in late-stage studies; Glaxo up 2% premarket
Two Phase 3 clinical trials, GEMINI-1 & 2, evaluating ViiV Healthcare's two-drug regimen of dolutegravir and lamivudine in adult patients with chronic HIV-1 infection with baseline viral loads less than 500K copies/mL demonstrated its non-inferiority to the three-drug regimen of dolute...
Source: SeekingAlpha
Date: June, 14 2018 07:52
ViiV Healthcare's HIV med Juluca OK'd in Europe
As expected, the European Commission approves ViiV Healthcare's Juluca (dolutegravir 50 mg/rilpivirine 25 mg) for the treatment of adults with HIV-1 infection who are virologically suppressed on a stable antiretroviral regimen for at least six months with no history of virological failure ...
Source: SeekingAlpha
Date: May, 21 2018 07:13
Shionogi & Co. Ltd. ADR 2017 Q4 - Results - Earnings Call Slides
The following slide deck was published by Shionogi & Co. Ltd. ADR in conjunction with their 2017 Q4 earnings Read more ...
Source: SeekingAlpha
Date: May, 10 2018 15:03
European advisory group backs ViiV Healthcare's two-drug HIV pill Juluca
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinion recommending approval for ViiV Healthcare's Juluca (dolutegravir/rilpivirine) for the treatment of HIV-1-infected adults who are virologically suppressed (HIV-1 RNA <50 copies...
Source: SeekingAlpha
Date: March, 23 2018 07:48
Shionogi & Co (SGIOY) Updates On Research And Development - Slideshow
The following slide deck was published by Shionogi & Co. Ltd. ADR in conjunction with this Read more ...
Source: SeekingAlpha
Date: March, 15 2018 13:47
Gilead's HIV med Biktarvy on par with Viiv's Triumeq in late-stage study
Results from a Phase 3 clinical trial, Study 1844, demonstrated the non-inferiority of Gilead Sciences' ( GILD -1% ) Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg) to ViiV Healthcare's Triumeq (abacavir 600 mg/dolutegravir 50 mg/lamivudine 300 mg) in vir...
Source: SeekingAlpha
Date: March, 05 2018 14:21

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-10N/A125.06N/AN/A92
2018-12-07128.00125.06128.00125.061,141
2018-12-06N/A126.03N/AN/A8,424
2018-12-05126.03126.03126.03126.03437
2018-12-04126.03126.03126.03126.03437

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-103923.2609Cover
2018-12-0781,1410.7011Cover
2018-12-03182477.2874Cover
2018-11-3020041348.4262Short
2018-11-29142355.9574Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SGIOY.


About Shionogi & Co. Ltd. (OTC: SGIOY)

Logo for Shionogi & Co. Ltd. (OTC: SGIOY)

Not available

 

Contact Information

 

 

Current Management

  • Isao Teshirogi Ph.D. / President
  • Motozo Shiono / Chairman

Current Share Structure

  • Market Cap: $18,434,648,663 - 03/09/2018
  • Issue and Outstanding: 351,136,165 - 03/31/2012

 



Daily Technical Chart for (OTC: SGIOY)

Daily Technical Chart for (OTC: SGIOY)


Stay tuned for daily updates and more on (OTC: SGIOY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: SGIOY)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SGIOY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of SGIOY and does not buy, sell, or trade any shares of SGIOY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/